- Home
- PASG
PASG
Passage Bio Inc.
as 03-28-2025 4:00pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 31.1M | IPO Year: | 2020 |
| Target Price: | $7.67 | AVG Volume (30 days): | 180.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $1.64 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Passage Bio Inc. (PASG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | PASG | CFO | Feb 10 '25 | Sell | $0.53 | 3,183 | $1,685.72 | 41,283 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Jan 10 '25 | Sell | $0.63 | 223,219 | $142,223.38 | 7,131,636 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Jan 6 '25 | Sell | $0.72 | 147,024 | $103,305.69 | 7,131,636 |
Latest Passage Bio Inc. News
PASG Breaking Stock News: Dive into PASG Ticker-Specific Updates for Smart Investing
Zacks
24 days ago
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
MT Newswires
a month ago
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating
GlobeNewswire
a month ago
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
a month ago
Passage Bio to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Simply Wall St.
3 months ago
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
TipRanks
4 months ago
Passage Bio assumed with an Outperform at Wedbush
MT Newswires
4 months ago
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
Compare PASG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.